Clinical trial
Post-marketing Observational Study in Subjects With Rheumatoid Arthritis
NCT00234884 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00234884 |
|---|---|
| Title | Post-marketing Observational Study in Subjects With Rheumatoid Arthritis |
| Official title | A Five-year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis Formerly Treated in Study M02-497 (ReAct) and Subsequently Prescribed Humira |
| Acronym | ReAlise |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological |
| Interventions | adalimumab |
| Enrollment | 3,435 |
| Start date | Sep 1, 2003 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Oct 10, 2005 |
| Last update posted | Sep 30, 2011 |
| Countries | Australia, Austria, Belgium, France, Germany, Greece, Italy, Netherlands, Portugal, Spain, United Kingdom |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: